PKTX News and Press, Protokinetix Inc From 06/07/19

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ) today announced reaching the midpoint of a Phase-1 first-in-human clinical trial of AAGP ® PKX-001 treated islet cells used in conjunction with the Edmonton Protocol for the treatment o...

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ) today announces that it will hold the first in a series of Town Hall Meetings . This meeting is being held to update shareholders on the current status of the company’s ongoing rese...

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ) is announcing that the Company has secured a partnership agreement with IMPART investigator team Canada at Dalhousie University and has now commenced studies to reveal the benefits of PKX-001...

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX ) has been requested by OTC Markets Group to comment on certain recent promotional activity encouraging investors to purchase the Company’s common shares. Th...

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ) updates its stockholders regarding phase 3 of testing using AAGP® in retinal cell replacement therapy at the University of British Columbia. The study is now using 2-animal models an...

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ) announces the launch of the third in a series of informational videos by the Principal Investigators in each field currently being tested. The third video is an update on the testing in t...